Cisplatino y riesgo de insuficiencia renal aguda

Abstract

Abstract:Cisplatin is a platinum-based antineoplastic, used as therapy in 30% of solid tumors, however, acute kidney injury is an adverse effect observed until in 20% of patients, which increases morbidity and deteriorates the prognosis of patients. In the present narrative review, recent studies on the incidence of and risk of acute renal failure in patients with baseline GFR normal and different types of cancer, which were administered different doses and cycles of Cisplatin. The degree of acute renal failure consequent to treatment was observed, In addition, the conditions that exacerbate nephrotoxicity were investigated, the mechanisms pathophysiological that lead to deterioration of renal function due to drug accumulation in renal tubules linked to cell affinity and flow, apoptosis, injury vascular disease, oxidative stress and inflammation, which make certain patients more prone. The effectiveness of currently applied and new complementary therapies was evaluated. alternatives that would improve the quality of life of patients and their evolution.